<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797823</url>
  </required_header>
  <id_info>
    <org_study_id>IRB4311</org_study_id>
    <nct_id>NCT00797823</nct_id>
  </id_info>
  <brief_title>Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone</brief_title>
  <official_title>A Comparison of Two Sensor-Augmented Glycemic Control Systems in Persons With Type 1 Diabetes Mellitus: Subcutaneous (SC) Insulin and Glucagon Delivery vs. SC Insulin Only</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Legacy Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Legacy Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to test an insulin and glucagon delivery algorithm designed to be used in
      conjunction with a continuous glucose monitoring system. This combined glucose
      sensing/hormone delivery approach is a step on the way to eventual development of an
      artificial (or automated) pancreas. The insulin and glucagon delivery algorithm is based on
      the difference between the current blood glucose and the target glucose (proportional error)
      and the rate of change in blood glucose (derivative error), both adjusted for the recent
      glucose history. This algorithm is called the Fading Memory Proportional-Derivative (FMPD)
      Algorithm. The principal investigator of this study has published previous research regarding
      the use of this algorithm and found it to be well-suited to control blood glucose in type 1
      diabetic animals. The addition of glucagon was helpful; better glycemic control with fewer
      glucose excursions were observed when small intermittent infusions of subcutaneous glucagon
      were given during times of impending low blood sugar (Ward et al. 2008).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the current human study is to compare glycemic control in persons with Type
      1 Diabetes using the FMPD Insulin plus Glucagon Delivery Algorithm vs. the FMPD Insulin-Alone
      Algorithm. Subjects will undergo two 28-hour sensor-augmented glycemic control studies. Each
      subject will be fitted with two short term continuous glucose monitoring systems and two
      subcutaneous (SC) infusion catheters. These catheters will allow for SC delivery of insulin
      and glucagon (or insulin plus a glucagon placebo). The accuracy of the wire sensors will be
      verified every 10 minutes with a venous blood glucose test. For the first 4 hours, the
      insulin and glucagon delivery will be controlled by venous blood in order to assess and
      compare the accuracy of the two sensors, after which the more accurate sensor (if it remains
      accurate) will control the FMPD algorithm. The main outcomes of our study are time spent in
      the target range (70 - 180 mg/dl) and the percentage of studies requiring intervention due to
      hypoglycemia (glucose &lt; 70 mg/dl). The accuracy of the sensors over the life of the study
      will also be evaluated.

      The specific system used in this study of frequent blood testing and the use of two separate
      infusion pumps is not feasible for every day use for individuals with diabetes. However, if
      the glucose control algorithm (with or without the use of glucagon) provides effective blood
      glucose management over long time periods the calculation program may be integrated into a
      continuous blood glucose monitoring system with an insulin and glucagon pump.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of Closed Loop Diabetes Control</measure>
    <time_frame>1 year</time_frame>
    <description>Effectiveness of closed loop diabetes control will be measured by mean glucose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Time Venous Blood Glucose &lt;70 mg/dl</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Insulin + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Glycemic control of subject participants was managed by the closed-loop system which delivered insulin and normal saline (instead of glucagon) as a placebo, based upon algorithm calculations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin + Glucagon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycemic control of subject participants was managed by the system which delivered insulin and glucagon based upon algorithm calculations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilot Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pilot studies designed to assess safety of the system. Includes 6 participants undergoing 7 studies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin, Asp(B28)-</intervention_name>
    <description>Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm</description>
    <arm_group_label>Insulin + Placebo</arm_group_label>
    <arm_group_label>Insulin + Glucagon</arm_group_label>
    <arm_group_label>Pilot Study</arm_group_label>
    <other_name>Aspart insulin</other_name>
    <other_name>Novolog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm</description>
    <arm_group_label>Insulin + Glucagon</arm_group_label>
    <arm_group_label>Pilot Study</arm_group_label>
    <other_name>Glucagen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution 0.9%</description>
    <arm_group_label>Insulin + Placebo</arm_group_label>
    <arm_group_label>Pilot Study</arm_group_label>
    <other_name>Normal saline, NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21-65, history of Type 1 Diabetes Mellitus for &gt; 3 months.

          -  Women:

               -  For women of childbearing potential, a negative urine pregnancy test is required
                  on the first day of the study prior to sensor insertion AND the subject must
                  agree to use contraception prior to and during the study.

               -  For menopausal women or those who have undergone surgical sterilization, no
                  pregnancy test or contraception will be required.

          -  Willingness to attend all clinic visits and participate in two 28-hour studies or one
             9-hour study.

          -  Hemoglobin A1C of 5.0-10%. (Values below 5.0 suggest a severe tendency towards
             hypoglycemia, and values above 10% suggest severely uncontrolled diabetes with risk
             for ketoacidosis.)

          -  Body mass index of 19-35.

        Exclusion Criteria:

          -  Pregnancy, lactation or refusal to use contraception.

          -  Use of any investigational drug during the 30 days prior to screening.

          -  Enrollment or participation in any other research studies 30 days prior to and during
             the entirety of sensor insertion.

          -  Current alcohol abuse, substance abuse, or severe mental illness (as judged by the
             Principal Investigator (PI)).

          -  Any prior cerebrovascular accident or major permanent neurological damage such as
             aphasia, hemiparesis, or dementia.

          -  A history of cerebrovascular disease or cardiovascular disease regardless of the time
             since occurrence.

          -  Coronary artery disease (symptomatic or asymptomatic) as manifested by unstable
             angina, acute coronary syndrome, myocardial infarction or therapeutic coronary
             procedure (e.g., Percutaneous Transluminal Coronary Angioplasty (PTCA), stent
             placement, Coronary Artery By-pass Grafting (CABG)) within the prior 6 months.

          -  Any degree of heart failure (as defined by New York Heart Association)..

          -  Renal insufficiency (serum creatinine of &gt; 2.5).

          -  Current foot or leg ulceration.

          -  Peripheral arterial disease with uncontrolled claudication.

          -  Active uncontrolled malignancy except basal cell or squamous cell skin cancers.

          -  Concurrent illness, other than diabetic mellitus, that is not controlled by a stable
             therapeutic regimen.

          -  Hemoglobin A1C of less than 5.0 or greater than 10%.

          -  A total bilirubin level above 1.5 mg/dl.

          -  Medications: Oral or parenteral corticosteroids (glucocorticoid therapy) are
             exclusions; topical corticosteroids are not.

          -  Any chronic immunosuppressive medication (such as cyclosporine, azathioprine,
             sirolimus, or tacrolimus).

          -  Visual impairment that would prevent reading the display of the Medtronic Guardian®
             Receiver.

          -  Physical impairment that would prevent using the buttons of the Medtronic Guardian®
             Receiver.

          -  Serum Alanine Transaminase (ALT) or Aspartate Transaminase (AST) ≥3x the upper limit
             of normal.

          -  Serum albumin level of &lt; 3.2 g/dl.

          -  Severe anemia as defined by a hematocrit of &lt; 28%.

          -  Severe serum electrolyte abnormality (sodium, potassium, carbon dioxide, chloride).

          -  Cardiac rhythm disturbance characterized by: 2nd or 3rd degree heart block,
             bradycardia of less than 50 bpm (exception of bradycardia in an aerobic athlete),
             tachycardia of greater than 100 bpm, or any arrhythmia judged by the investigator to
             be exclusionary.

          -  A history of Human Immunodeficiency Virus (HIV) infection.

          -  An active hepatitis infection.

          -  Known allergy to any type of insulin

          -  Insulin resistance requiring more than 200 units of insulin per day

          -  Known bleeding disorders or chronic usage of warfarin.

          -  Any known seizure disorder.

          -  Past history of pheochromocytoma or a family history of Multiple Endocrine Neoplasia
             (MEN) 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease.

          -  Hypoglycemic unawareness or chronic hypoglycemia.

          -  A severe hypoglycemic event which required hospitalization within the past two years.

          -  Adrenal insufficiency.

          -  Insulinoma.

          -  Use of both acetaminophen and ascorbic acid.

          -  Impaired mentation or psychiatric diagnoses

          -  Uncontrolled candidiasis.

          -  Any known allergy to glucagon.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William K. Ward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Legacy Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Legacy Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <results_first_submitted>June 24, 2011</results_first_submitted>
  <results_first_submitted_qc>August 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2011</results_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Legacy Health System</investigator_affiliation>
    <investigator_full_name>W. Kenneth Ward</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>pancreas</keyword>
  <keyword>beta cell</keyword>
  <keyword>glucagon</keyword>
  <keyword>insulin</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the Oregon Health and Science University (OHSU) outpatient clinics in Portland, Oregon.</recruitment_details>
      <pre_assignment_details>A total of 22 studies in 14 subjects were performed. 6 subjects participated in 7 9-hour pilot studies, 6 with insulin and glucagon and 1 with insulin + placebo to assess the safety of the protocol. 8 subjects then underwent 2 interventional studies each for a total of 16 studies, one with insulin and placebo and one with insulin and glucagon.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin + Glucagon -&gt; Insulin + Placebo)</title>
          <description>This group consists of x participants initially randomized to the insulin plus glucagon (latter to prevent hypoglycemia) intervention for glycemic control of type 1 diabetes during the first period, then insulin plus placebo in the second period. The control system was comprised of glucose sensors, a computer algorithm, and actuator pumps in a circuit meant to automatically adjust insulin and glucagon infusion rates based on glucose values delivered to the algorithm (a closed-loop system, as it is meant to exclude human intervention).</description>
        </group>
        <group group_id="P2">
          <title>Insulin + Placebo -&gt; Insulin + Glucagon</title>
          <description>This group consists of x participants initially randomized to the insulin plus placebo intervention for glycemic control of type 1 diabetes during the first period, then insulin plus glucagon (latter to prevent hypoglycemia) in the second period. The control system was comprised of glucose sensors, a computer algorithm, and actuator pumps in a circuit meant to automatically adjust insulin and glucagon infusion rates based on glucose values delivered to the algorithm (a closed-loop system, as it is meant to exclude human intervention).</description>
        </group>
        <group group_id="P3">
          <title>Pilot</title>
          <description>Pilot studies included 6 participants, one of whom underwent an insulin + glucagon and an insulin + placebo study, while 5 underwent only one insulin + glucagon study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pilot Studies</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Not involved in pilot studies</participants>
                <participants group_id="P2" count="0">Not involved in pilot studies</participants>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Period (Initial Randomization)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0">Pilot studies only performed during initial period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Period (Crossover)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin + Glucagon -&gt; Insulin + Placebo)</title>
          <description>This group consists of x participants initially randomized to the insulin plus glucagon (latter to prevent hypoglycemia) intervention for glycemic control of type 1 diabetes during the first period, then insulin plus placebo in the second period. The control system was comprised of glucose sensors, a computer algorithm, and actuator pumps in a circuit meant to automatically adjust insulin and glucagon infusion rates based on glucose values delivered to the algorithm (a closed-loop system, as it is meant to exclude human intervention).</description>
        </group>
        <group group_id="B2">
          <title>Insulin + Placebo -&gt; Insulin + Glucagon</title>
          <description>This group consists of x participants initially randomized to the insulin plus placebo intervention for glycemic control of type 1 diabetes during the first period, then insulin plus glucagon (latter to prevent hypoglycemia) in the second period. The control system was comprised of glucose sensors, a computer algorithm, and actuator pumps in a circuit meant to automatically adjust insulin and glucagon infusion rates based on glucose values delivered to the algorithm (a closed-loop system, as it is meant to exclude human intervention).</description>
        </group>
        <group group_id="B3">
          <title>Pilot</title>
          <description>Pilot studies included 6 participants, one of whom underwent an insulin + glucagon and an insulin + placebo study, while 5 underwent only one insulin + glucagon study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="10.5"/>
                    <measurement group_id="B2" value="39.8" spread="10.7"/>
                    <measurement group_id="B3" value="35.1" spread="17.4"/>
                    <measurement group_id="B4" value="36.7" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness of Closed Loop Diabetes Control</title>
        <description>Effectiveness of closed loop diabetes control will be measured by mean glucose.</description>
        <time_frame>1 year</time_frame>
        <population>The number of participants for analysis was determined was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Insulin Alone</title>
            <description>No glucagon given during closed loop control-insulin only</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator: Insulin Plus Glucagon</title>
            <description>Insulin plus glucagon given (latter to prevent hypoglycemia) for closed loop control.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Closed Loop Diabetes Control</title>
          <description>Effectiveness of closed loop diabetes control will be measured by mean glucose.</description>
          <population>The number of participants for analysis was determined was per protocol.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.9" spread="5.0"/>
                    <measurement group_id="O2" value="149.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Time Venous Blood Glucose &lt;70 mg/dl</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator: Insulin Alone</title>
            <description>No glucagon given during closed loop control-insulin only</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator: Insulin Plus Glucagon</title>
            <description>Insulin plus glucagon given (latter to prevent hypoglycemia) for closed loop control.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Time Venous Blood Glucose &lt;70 mg/dl</title>
          <units>percent of time</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.67"/>
                    <measurement group_id="O2" value="1.15" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 1 year for entire research period, and over the study period for each individual study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Insulin + Glucagon -&gt; Insulin + Placebo)</title>
          <description>This group consists of x participants initially randomized to the insulin plus glucagon (latter to prevent hypoglycemia) intervention for glycemic control of type 1 diabetes during the first period, then insulin plus placebo in the second period. The control system was comprised of glucose sensors, a computer algorithm, and actuator pumps in a circuit meant to automatically adjust insulin and glucagon infusion rates based on glucose values delivered to the algorithm (a closed-loop system, as it is meant to exclude human intervention).</description>
        </group>
        <group group_id="E2">
          <title>Insulin + Placebo -&gt; Insulin + Glucagon</title>
          <description>This group consists of x participants initially randomized to the insulin plus placebo intervention for glycemic control of type 1 diabetes during the first period, then insulin plus glucagon (latter to prevent hypoglycemia) in the second period. The control system was comprised of glucose sensors, a computer algorithm, and actuator pumps in a circuit meant to automatically adjust insulin and glucagon infusion rates based on glucose values delivered to the algorithm (a closed-loop system, as it is meant to exclude human intervention).</description>
        </group>
        <group group_id="E3">
          <title>Pilot</title>
          <description>Pilot studies included 6 participants, one of whom underwent an insulin + glucagon and an insulin + placebo study, while 5 underwent only one insulin + glucagon study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Hypoglycemia</sub_title>
                <description>Venous blood glucose &lt; 60 mg/dl, requiring treatment with intravenous (IV) dextrose.</description>
                <counts group_id="E1" events="55" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="67" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Nausea reported by patient (+/- vomiting), related to glucagon administration.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>W Kenneth Ward MD</name_or_title>
      <organization>Legacy Health System</organization>
      <phone>503-413-5171</phone>
      <email>wardk@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

